Interleukin 28B genotype and insulin resistance in chronic hepatitis C patients.

Abstract:

BACKGROUND:In patients with chronic HCV infection, an association between IL28B genotype and insulin-resistance (IR), known predictors of sustained virological response (SVR) to pegylated interferon (PEG-IFN) and ribavirin (RBV) therapy, has been reported. The aim of this study was to investigate the association of IR and IL28B genotype in two cohorts of well-characterized HCV patients. METHODS:A total of 480 non-diabetic HCV patients were analysed: 391 patients who received PEG-IFN/RBV in the MIST study and 89 previously reported patients followed at a metabolic liver diseases centre (Division of Internal Medicine, Fondazione IRCCS Ospedale Maggiore Policlinico, Milan, Italy). All were tested for IL28B rs12979860 single nucleotide polymorphism by real-time PCR and had IR measured by HOMA-IR. Staging of liver disease through liver biopsy was available for all patients. RESULTS:Overall, 164 patients (34%) were IL28B CC. Mean HOMA-IR values (±sd) did not differ according to IL28B genotype, being respectively 1.14 ±0.79 in CC versus 1.14 ±0.78 in CT/TT (P=1.0) in the first, and 2.4 ±1.0 versus 2.5 ±1.0 (P=0.7) in the second cohort. HOMA-IR>2 was not associated with IL28B genotype: 16/132 (12%) CC versus 31/259 (12%) CT/TT (P=1.0) in the first cohort and 16/32 (50%) versus 37/57 (65%; P=0.18) in the second. This held true also when using different HOMA cutoffs (>2.5, >3.0, >3.5 and >4.0). In the MIST cohort, HOMA-IR>2 did not influence treatment outcome, SVR rates being 28/47 (60%) in HOMA-IR>2 versus 214/344 (62%) in HOMA-IR≤2 (P=0.8). IL28B genotype was a strong predictor of SVR: 84% (111/132) in CC versus 51% (131/259) in CT/TT patients (P<0.0001). CONCLUSIONS:In two cohorts of non-diabetic HCV patients where IL28B genotype predicted treatment outcome, we found no association between IL28B genotype and HOMA-IR.

journal_name

Antivir Ther

journal_title

Antiviral therapy

authors

Degasperi E,Valenti L,Aghemo A,De Francesco R,Rumi M,Soffredini R,Donnici L,Cheroni C,Fargion S,Zanoni V,Orsi E,Colombo M

doi

10.3851/IMP2743

subject

Has Abstract

pub_date

2014-01-01 00:00:00

pages

747-53

issue

8

eissn

1359-6535

issn

2040-2058

journal_volume

19

pub_type

杂志文章
  • Antiviral therapy reduces risk of haemorrhagic stroke in patients with HCV infection: a nationwide cohort study.

    abstract:BACKGROUND:The tendency for haemorrhagic stroke in patients with chronic HCV infection has emerged recently but the finding may be confounded by comorbidities. Proving the causality between HCV infection and haemorrhagic stroke is mandatory. Our study was designed to investigate the incidence of intracranial haemorrhag...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP3172

    authors: Lin MS,Chung CM,Lin WY,Wei KL,Wang J,Lee YY,Hu JH,Tung TH,Lin YS

    更新日期:2018-01-01 00:00:00

  • Antiretoviral therapy and the lipodystrophy syndrome, part 2: concepts in aetiopathogenesis.

    abstract::Clinical research has indicated that the use of nucleoside reverse transcriptase inhibitor (NRTI) and HIV protease inhibitor (PI) therapy is associated with a risk of long-term toxicity syndromes, and that the aetiopathogenesis of these adverse effects is independent of the antiretroviral effects of these drugs. In re...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,评审

    doi:

    authors: Nolan D,John M,Mallal S

    更新日期:2001-09-01 00:00:00

  • Factors associated with HIV RNA levels in pregnant women on non-suppressive highly active antiretroviral therapy at conception.

    abstract:BACKGROUND:Little is known about pregnancy patterns and levels of HIV RNA in HIV-infected women conceiving on highly active antiretroviral therapy (HAART) with non-suppressed viral load (VL), nor about their therapeutic management. METHODS:Linear mixed models were fitted to study changes in VL and potential associated...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,多中心研究

    doi:10.3851/IMP1489

    authors: European Collaborative Study.

    更新日期:2010-01-01 00:00:00

  • Characterization of HCV resistance from a 3-day monotherapy study of voxilaprevir, a novel pangenotypic NS3/4A protease inhibitor.

    abstract:BACKGROUND:Voxilaprevir (VOX; GS-9857) is a pangenotypic HCV NS3/4A protease inhibitor (PI) with potent antiviral activity against HCV genotypes (GTs) 1-6 and improved coverage of GT1 NS3 resistance-associated substitutions (RAS) associated with other HCV PIs. In a 3-day Phase Ib monotherapy study in patients infected ...

    journal_title:Antiviral therapy

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.3851/IMP3202

    authors: Lawitz E,Yang JC,Stamm LM,Taylor JG,Cheng G,Brainard DM,Miller MD,Mo H,Dvory-Sobol H

    更新日期:2018-01-01 00:00:00

  • HIV genotypic resistance testing to optimize antiretroviral prescribing: is there room for improvement?

    abstract:BACKGROUND:Clinical utilization of genotype resistance testing is evolving. We examined the extent to which HIV care providers requesting genotype resistance tests used the information appropriately and the impact of inappropriate utilization. METHODS:Data from a prospective cohort of HIV-infected patients (the HIV Ou...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:

    authors: Uy J,Brooks JT,Baker R,Hoffman M,Moorman A,Novak R,HOPS Investigators.

    更新日期:2007-01-01 00:00:00

  • Meta-analysis of mutations in the NS5A gene and hepatitis C virus resistance to interferon therapy: uniting discordant conclusions.

    abstract:BACKGROUND:Hepatitis C virus genotype 1B responds poorly to treatment with interferon, in contrast to the more interferon-sensitive genotypes 2 and 3. Studies on combination therapy regimens with PEG-interferon and ribavirin report sustained response rates that generally do not exceed 50%, in contrast to sustained resp...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,meta分析

    doi:

    authors: Schinkel J,Spaan WJ,Kroes AC

    更新日期:2004-04-01 00:00:00

  • Lower limb high arterial flow induced by tenofovir and emtricitabine treatment.

    abstract::Here, we describe a case of an HIV-infected patient with right lower limb oedema that appeared after initiation of tenofovir and emtricitabine treatment. The patient was fully investigated by serial heart and vessel echo-Doppler examination. Oedema of the lower limb was attributed to a transient drug-induced fivefold ...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP1302

    authors: Periard D,Yerly P,Hayoz D,Mazzolai L,Widmeier A,Cavassini M

    更新日期:2009-01-01 00:00:00

  • Treatment of primary HIV infection: a pilot study of stavudine and didanosine plus nevirapine with or without hydroxyurea.

    abstract::Treatment of primary human immunodeficiency virus (HIV) infection (PHI) may provide an opportunity to achieve a long lasting suppression of viral replication. Although there is growing evidence of the benefit of treating PHI, clinical data are still very limited. Special therapeutic considerations in this clinical set...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:

    authors: Zala C,Salomón H,Cahn P

    更新日期:1999-01-01 00:00:00

  • Predictive value of codon 215 reverse transcriptase mutation on the efficacy of didanosine in HIV-infected, zidovudine-experienced patients.

    abstract::We investigated whether or not mutations at codon 215 in the HIV reverse-transcriptase-encoding gene predicted a lower efficacy of didanosine therapy, as defined by survival of patients and change in CD4 cell counts in 121 HIV-infected, zidovudine-experienced patients. A trend for shorter survival, although not reachi...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:

    authors: Yerly S,Denereaz N,Mermillod B,Hirschel B,Perrin L

    更新日期:1996-08-01 00:00:00

  • Glycated haemoglobin in diabetic women with and without HIV infection: data from the Women's Interagency HIV Study.

    abstract:BACKGROUND:Limited data suggest that glycated haemoglobin (haemoglobin A1c; A1C) values might not reflect glycaemic control accurately in HIV-infected individuals with diabetes. METHODS:We evaluated repeated measures of paired fasting glucose and A1C values in 315 HIV-infected and 109 HIV-uninfected diabetic participa...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP1557

    authors: Glesby MJ,Hoover DR,Shi Q,Danoff A,Howard A,Tien P,Merenstein D,Cohen M,Golub E,Dehovitz J,Nowicki M,Anastos K

    更新日期:2010-01-01 00:00:00

  • K65R with and without S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine.

    abstract::Antiretroviral treatment with three nucleoside reverse transcriptase inhibitors (NRTIs) is widely used, but the combination of abacavir, didanosine and stavudine has never been investigated. We describe the surprising and consistent genotypic and phenotypic outcome in patients failing this combination. As part of a Da...

    journal_title:Antiviral therapy

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:

    authors: Røge BT,Katzenstein TL,Obel N,Nielsen H,Kirk O,Pedersen C,Mathiesen L,Lundgren J,Gerstoft J

    更新日期:2003-04-01 00:00:00

  • The host-pathogen interaction during HBV infection: immunological controversies.

    abstract::HBV is a hepatotropic and non-cytopathic virus that causes more than one million deaths annually from liver cirrhosis and hepatocellular carcinoma. As the virus itself is non-cytopathic, it is widely accepted that both viral control and liver pathology are mediated by the host immune system. Until recently, the focus ...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,评审

    doi:10.3851/IMP1620

    authors: Bertoletti A,Maini MK,Ferrari C

    更新日期:2010-01-01 00:00:00

  • Survival after long-term ART exposure: findings from an Asian patient population retained in care beyond 5 years on ART.

    abstract:BACKGROUND:This study investigated survival in people living with HIV being followed-up from 5 and 10 years after antiretroviral therapy (ART) initiation in a multi-country Asian cohort. METHODS:We included patients in follow-up >5 years after ART initiation. Factors associated with mortality beyond 5 and 10 years on ...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP3358

    authors: Bijker R,Kiertiburanakul S,Kumarasamy N,Pujari S,Sun LP,Ng OT,Lee MP,Choi JY,Nguyen KV,Chan YJ,Merati TP,Cuong DD,Ross J,Jiamsakul A,IeDEA Asia-Pacific.

    更新日期:2020-01-01 00:00:00

  • Ribavirin monitoring in chronic hepatitis C therapy: anaemia versus efficacy.

    abstract::The standard treatment of HCV infection with pegylated interferon-alpha2a or -alpha2b and ribavirin is effective in <50% of HCV genotype-1-infected patients. To improve this figure, it might be desirable to obtain optimal plasma concentrations of the drug by increasing the dose. Unfortunately, there is great interpati...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,评审

    doi:10.3851/IMP1609

    authors: Brochot E,Castelain S,Duverlie G,Capron D,Nguyen-Khac E,François C

    更新日期:2010-01-01 00:00:00

  • Incidence of liver cirrhosis in HIV-infected patients with chronic hepatitis B or C in the era of highly active antiretroviral therapy.

    abstract:BACKGROUND:Longitudinal assessment of liver fibrosis with transient elastometry (TE) in patients with chronic viral hepatitis is becoming routine clinical practice in many clinics, as this procedure is non-invasive, easy to perform and relatively inexpensive, allowing early detection of cirrhosis. Herein, we examine th...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP1630

    authors: Tuma P,Medrano J,Resino S,Vispo E,Madejón A,Sánchez-Piedra C,Rivas P,Labarga P,Martín-Carbonero L,Barreiro P,Soriano V

    更新日期:2010-01-01 00:00:00

  • Treatment of pegylated interferon-α2a in chronic hepatitis B patients demonstrating a spontaneous decline in HBV DNA after acute exacerbation.

    abstract:BACKGROUND:Acute exacerbation (AE) in chronic hepatitis B (CHB) is usually followed by a spontaneous decline in HBV DNA levels. The subsequent treatment is controversial. In this study, we evaluated the efficacy and safety of pegylated interferon-α2a (PEG-IFN-α2a) for such CHB patients. METHODS:A total of 74 hepatitis...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP2832

    authors: Cai Q,Chen F,Shao X,Zhang X,Zhao Z,Gao Z

    更新日期:2015-01-01 00:00:00

  • HBV carrying drug-resistance mutations in chronically infected treatment-naive patients.

    abstract:BACKGROUND:Nucleoside/nucleotide analogue (NA) treatment causes selection pressure for HBV strains carrying mutations conferring NA resistance. Drug-resistance mutations occur in the reverse transcriptase (RT) region of the HBV polymerase gene and spontaneously arise during viral replication. These mutations can also a...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,多中心研究

    doi:10.3851/IMP2938

    authors: Gomes-Gouvêa MS,Ferreira AC,Teixeira R,Andrade JR,Ferreira AS,Barros LM,Rezende RE,Nastri AC,Leite AG,Piccoli LZ,Galvan J,Conde SR,Soares MC,Kliemann DA,Bertolini DA,Kunyoshi AS,Lyra AC,Oikawa MK,de Araújo LV,Carril

    更新日期:2015-01-01 00:00:00

  • Viro-immunological response of drug-naive HIV-1-infected patients starting a first-line regimen with viraemia >500,000 copies/ml in clinical practice.

    abstract:BACKGROUND:Virological success (VS) and immunological reconstitution (IR) of antiretroviral-naive HIV-1-infected patients with pre-therapy viral load (VL) >500,000 copies/ml was assessed after 12 months of treatment according to initial drug-class regimens. METHODS:An observational multicentre retrospective study was ...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP3197

    authors: Santoro MM,Di Carlo D,Armenia D,Zaccarelli M,Pinnetti C,Colafigli M,Prati F,Boschi A,Antoni AMD,Lagi F,Sighinolfi L,Gervasoni C,Andreoni M,Antinori A,Mussini C,Perno CF,Borghi V,Sterrantino G

    更新日期:2018-01-01 00:00:00

  • Fate and function of hepatitis-C-virus-specific T-cells during peginterferon-alpha2b therapy for acute hepatitis C.

    abstract:BACKGROUND:Strong hepatitis C virus (HCV)-specific T-cell responses are associated with spontaneous clearance of acute hepatitis C. However, recent studies described a decline in HCV-specific CD8+ T-cells during interferon treatment, suggesting that the success of acute HCV therapy might be independent of adaptive immu...

    journal_title:Antiviral therapy

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Wiegand J,Cornberg M,Aslan N,Schlaphoff V,Sarrazin C,Kubitschke A,Buggisch P,Ciner A,Jaeckel E,Manns MP,Wedemeyer H

    更新日期:2007-01-01 00:00:00

  • Valganciclovir as pre-emptive therapy for cytomegalovirus infection in allogeneic haematopoietic stem cell transplant recipients.

    abstract:BACKGROUND:In haematopoietic stem cell transplant (HSCT) recipients, cytomegalovirus (CMV) infection contributes significantly to morbidity and mortality in both the early and late post-transplant period. Ganciclovir (GCV) is the treatment of choice for CMV, but requires intravenous administration, a fact that complica...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP1858

    authors: Ruiz-Camps I,Len O,de la Cámara R,Gurguí M,Martino R,Jarque I,Barrenetxea C,Díaz de Heredia C,Batlle M,Rovira M,de la Torre J,Torres A,Aguilar M,Espigado I,Martín-Dávila P,Bou G,Borrell N,Aguado JM,Pahissa A,Spanish

    更新日期:2011-01-01 00:00:00

  • Do we need genotypic weighted resistance scores for antiretrovirals? The curious case of tipranavir.

    abstract::Weighted genotypic resistance scores represent a step towards excellence in the interpretation of HIV type-1 (HIV-1) resistance to antiretroviral drugs. They can predict phenotypic resistance and clinical response better than any other unweighted score. With the addition of mutations associated with an increased respo...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP1671

    authors: Llibre JM

    更新日期:2010-01-01 00:00:00

  • In combination, nucleoside reverse transcriptase inhibitors have significant effects on 3T3-L1 adipocyte lipid accumulation and survival.

    abstract::The use of nucleoside reverse transcriptase inhibitors (NRTIs) for the treatment of HIV infection is clearly linked to the development of subcutaneous fat atrophy. Until recently, however, in vitro studies of adipocytes have shown no or only modest and inconsistent effects of these agents on adipocyte biology. This is...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:

    authors: Kosmiski LA,Miller HL,Klemm DJ

    更新日期:2006-01-01 00:00:00

  • Pre-existing mutations in the rilpivirine Phase III trials ECHO and THRIVE: prevalence and impact on virological response.

    abstract:BACKGROUND:Rilpivirine (RPV), a non-nucleoside reverse transcriptase inhibitor (NNRTI), was approved for HIV-1 infected, antiretroviral treatment-naive adults based on data from two Phase III trials. In the screening population, the prevalence of 49 NNRTI resistance-associated mutations (RAMs) and the impact of allowed...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,随机对照试验

    doi:10.3851/IMP2358

    authors: Vingerhoets J,Rimsky L,Van Eygen V,Nijs S,Vanveggel S,Boven K,Picchio G

    更新日期:2013-01-01 00:00:00

  • Acute renal failure related to high doses of acyclovir (15 mg/kg/8 h) during treatment of varicella zoster virus encephalitis.

    abstract::Varicella zoster virus (VZV) is less susceptible than herpes simplex virus to acyclovir. The optimal acyclovir regimen during VZV encephalitis remains unknown. We report two cases of acute renal failure after an increase in acyclovir dosage from 10 mg to 15 mg/kg/8 h during the treatment of VZV encephalitis according ...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP3313

    authors: Martinot M,Klein A,Demesmay K,Groza M,Mohseni-Zadeh M,Tebacher-Alt M,Fafi-Kremer S

    更新日期:2019-01-01 00:00:00

  • The potential role of HCV core antigen testing in diagnosing HCV infection.

    abstract::The potential uses of serological tests that detect HCV core antigens in biological fluids are highlighted. The most common serological tests utilized to detect exposure to HCV rely on the detection of antibodies to HCV. However, these tests cannot distinguish between individuals who have resolved their infection and ...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,评审

    doi:10.3851/IMP2463

    authors: Dawson GJ

    更新日期:2012-01-01 00:00:00

  • Viral hepatitis and HIV: update and management.

    abstract::HCV-related liver disease is an important contributor to morbidity and mortality in the HIV-infected population. Successful treatment of HIV-HCV-coinfected patients is followed by favourable clinical outcomes. While the combination of pegylated interferon and ribavirin remains the mainstay in the treatment of non-1 HC...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,评审

    doi:10.3851/IMP2601

    authors: Núñez M,Mendes-Correa MC

    更新日期:2013-01-01 00:00:00

  • HIV-1 genital shedding in HIV-infected patients randomized to second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir.

    abstract:BACKGROUND:HIV-1 shedding in genital secretions is associated with HIV transmission risk. Limited data exist on the effect of second-line lopinavir/ritonavir monotherapy (mLPV/r) on genital secretion of HIV RNA. METHODS:We measured HIV-1 in genital secretions of HIV-infected adults at time of failure from non-nucleosi...

    journal_title:Antiviral therapy

    pub_type: 临床试验,杂志文章

    doi:10.3851/IMP2737

    authors: Bunupuradah T,Bowonwattanuwong C,Jirajariyavej S,Munsakul W,Klinbuayaem V,Sophonphan J,Mahanontharit A,Hirschel B,Ruxrungtham K,Ananworanich J,HIV STAR Study team.

    更新日期:2014-01-01 00:00:00

  • Evolution of renal function in African patients initiating second-line antiretroviral treatment: findings from the ANRS 12169 2LADY trial.

    abstract:BACKGROUND:To investigate change in renal function in African patients initiating second-line antiretroviral therapy (ART) including ritonavir-boosted protease inhibitor (PI/r) with or without tenofovir disoproxil fumarate (TDF). METHODS:HIV-1-positive adults, failing standard first-line ART were randomized to either ...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP3097

    authors: Cournil A,Hema A,Eymard-Duvernay S,Ciaffi L,Badiou S,Kabore FN,Diouf A,Ayangma L,Le Moing V,Reynes J,Koulla-Shiro S,Delaporte E,2LADY Study Group.

    更新日期:2017-01-01 00:00:00

  • Evolution and predictors of HIV type-1 drug resistance in patients failing combination antiretroviral therapy in Italy.

    abstract:BACKGROUND:This study aimed to examine the evolution of genotypic drug resistance prevalence in treatment-failing patients in the multicentre, Italian, Antiretroviral Resistance Cohort Analysis (ARCA). METHODS:Patients with a drug resistance genotype test performed between 1999 and 2006 at failure of a combination ant...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,多中心研究

    doi:

    authors: Di Giambenedetto S,Zazzi M,Corsi P,Gonnelli A,Di Pietro M,Giacometti A,Almi P,Trezzi M,Boeri E,Gianotti N,Menzo S,Del Gobbo R,Francisci D,Nerli A,Galli L,De Luca A,Antiretroviral Resistance Cohort Analysis Study Group.

    更新日期:2009-01-01 00:00:00

  • Drug-drug interactions in HIV therapy: is it all clear?

    abstract::Drug-drug interactions in HIV therapy have been known to the clinic from earliest days of HIV treatment. Hundreds of well-designed pharmacokinetic studies have been performed in either HIV-infected patients or, mostly, in healthy volunteers. Case reports generally are graded lower in terms of evidence-based medicine b...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP2688

    authors: Burger D,Back D

    更新日期:2013-01-01 00:00:00